Literature DB >> 14767270

Renal vein or inferior vena caval extension in patients with renal cortical tumors: impact of tumor histology.

Farhang Rabbani1, Payam Hakimian, Victor E Reuter, Rachel Simmons, Paul Russo.   

Abstract

PURPOSE: We determined the prognostic significance of renal vein or inferior vena caval (IVC) extension in patients with nonmetastatic renal cell carcinoma (RCC) or oncocytoma undergoing surgery.
MATERIALS AND METHODS: The charts of patients undergoing radical or partial nephrectomy from 1989 to 2001 for nonmetastatic RCC or oncocytoma were retrospectively reviewed. A total of 1082 patients (1120 renal units) underwent radical (850 renal units) or partial (270 renal units) nephrectomy.
RESULTS: Renal vein extension was present in 60 patients (65.9%) and IVC extension was present in 31 (34.1%). The histological type associated with an increased risk of renal vein/IVC extension was conventional (80 of 702 cases, p <0.0001) and histological types with a decreased risk were oncocytoma (0 of 117, p = 0.00052) and papillary histology (0 of 146, p <0.0001). The 5-year actuarial recurrence-free probability was 59%, 65% and 91% in patients with IVC extension, renal vein extension and no renal vein or IVC extension, respectively. Larger tumor size, nodal metastases and conventional histology were associated with an increased risk of recurrence (RR = 3.38, 95% CI 2.53 to 4.51 for a doubling in size, RR = 9.97, 95% CI 5.51 to 18.1 and RR 3.78, 95% CI 2.15 to 6.65) as well as death (RR = 1.44, 95% CI 1.20 to 1.74 for a doubling in size, RR = 5.39, 95% CI 2.86 to 10.2 and RR = 1.56, 95% CI 1.09 to 2.24, respectively).
CONCLUSIONS: Conventional RCC is associated with an increased risk, and oncocytoma and papillary histology are associated with a decreased risk of renal vein or IVC extension. Renal vein or IVC extension alone does not impart a worse prognosis independent of tumor size, nodal status and histology.

Entities:  

Mesh:

Year:  2004        PMID: 14767270     DOI: 10.1097/01.ju.0000112885.66352.e2

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  5 in total

1.  Radical nephrectomy with vena caval thrombectomy: a contemporary experience.

Authors:  Matthew G Kaag; Christien Toyen; Paul Russo; Angel Cronin; R Houston Thompson; Jeffrey Schiff; Melanie Bernstein; Manjit Bains
Journal:  BJU Int       Date:  2010-09-30       Impact factor: 5.588

2.  Precise control of caval and hepatic vessels: Surgical technique to treat level III caval thrombus concomitant to renal cell carcinoma.

Authors:  Ming Chen; Bin Xu; Ning Liu; Hua Jiang; Yiduo Wang; Yu Yang; Xiaowen Zhang; Chao Sun; Jing Liu; Weidong Zhu; Shuqiu Chen
Journal:  Can Urol Assoc J       Date:  2015-11-04       Impact factor: 1.862

3.  Cytoreductive nephrectomy with thrombectomy before targeted therapy improves survival for metastatic renal cell carcinoma with venous tumor thrombus: a single-center experience.

Authors:  Nienie Qi; Pengjie Wu; Jinchao Chen; Teng Li; Xianghui Ning; Jin Wang; Kan Gong
Journal:  World J Surg Oncol       Date:  2017-01-05       Impact factor: 2.754

4.  Influence of tumor size in the progression of venous tumor thrombus in renal cell carcinoma: A 7-year single-center experience.

Authors:  Mathisekaran Thangarasu; J Sanjay Prakash; Sandeep Bafna; P Aarthy; Thirumalai Ganesan Govindaswamy; Balaji Venugopal; Ananthakrishnan Sivaraman; Nitesh Jain; Arunkumar Balakrishnan; Deepak Raghavan; Murali Venkatraman; M Chandranathan; Rajesh Paul; Nivash Selvaraj; Balasubramaniam Ramakrishnan; Narasimhan Ragavan
Journal:  Urol Ann       Date:  2022-07-18

5.  Increased risk of preoperative venous thromboembolism in patients with renal cell carcinoma and tumor thrombus.

Authors:  D W Yokom; R Ihaddadene; P Moretto; C M Canil; N Reaume; G Le Gal; M Carrier
Journal:  J Thromb Haemost       Date:  2014-02       Impact factor: 5.824

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.